Get the Stockscreener App
46.47
2.50%
-1.19
After Hours:
46.47
Sanofi Adr stock is traded at $46.47, with a volume of 4.36M.
It is down -2.50% in the last 24 hours and down -2.15% over the past month.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
See More
Previous Close:
$47.66
Open:
$46.71
24h Volume:
4.36M
Relative Volume:
1.20
Market Cap:
$112.23B
Revenue:
$49.41B
Net Income/Loss:
$5.59B
P/E Ratio:
19.46
EPS:
2.3875
Net Cash Flow:
$8.32B
1W Performance:
-1.78%
1M Performance:
-2.15%
6M Performance:
-6.86%
1Y Performance:
-17.78%
1-Day Range:
$46.00
$46.87
1-Week Range:
$46.00
$48.75
52-Week Range:
$44.62
$60.12
Sanofi Adr Stock (SNY) Company Profile
Name
Sanofi Adr
Sector
Industry
Phone
-
Address
-
Compare SNY vs LLY, JNJ, ABBV, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
46.47 | 115.10B | 49.41B | 5.59B | 8.32B | 2.3875 |
|
LLY
Lilly Eli Co
|
1,007.73 | 909.04B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
246.75 | 599.00B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
233.86 | 414.21B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
164.18 | 318.41B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
201.76 | 315.94B | 58.80B | 10.24B | 8.98B | 3.2788 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-27-26 | Initiated | Citigroup | Neutral |
| Jan-16-26 | Downgrade | UBS | Buy → Neutral |
| Jan-06-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-09-25 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-08-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-02-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Mar-21-25 | Initiated | Goldman | Neutral |
| Jan-30-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Jul-26-24 | Reiterated | Argus | Buy |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-05-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-30-23 | Downgrade | Stifel | Buy → Hold |
| Sep-06-23 | Upgrade | Berenberg | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-28-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-27-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-13-22 | Resumed | Morgan Stanley | Overweight |
| Aug-12-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-09-22 | Downgrade | UBS | Buy → Neutral |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Sep-27-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-15-21 | Initiated | Deutsche Bank | Sell |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Mar-17-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-11-20 | Upgrade | Goldman | Neutral → Buy |
| Feb-11-20 | Initiated | SVB Leerink | Mkt Perform |
| Jan-06-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-20-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-03-19 | Initiated | Bernstein | Outperform |
| Aug-14-19 | Upgrade | UBS | Neutral → Buy |
| Dec-11-18 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-10-18 | Upgrade | Citigroup | Neutral → Buy |
| Mar-23-18 | Upgrade | Liberum | Hold → Buy |
| Jan-23-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-06-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-01-17 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Nov-15-17 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-30-17 | Upgrade | HSBC Securities | Reduce → Hold |
View All
Sanofi Adr Stock (SNY) Latest News
MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot - Finviz
Antibiotics Market - GlobeNewswire Inc.
Sanofi (SNY) and Regeneron's Dupixent Recommended for EU Approval - Finviz
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates - Finviz
Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness - GlobeNewswire Inc.
How Do Investors Really Feel About Sanofi SA? - Sahm
CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans - Finviz
BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market - Finviz
Sanofi's (SNY) R&D Track Record Remains Investor Concern, Says BofA - Finviz
Manuela Buxo To Become Head of Sanofi's (SNY) Specialty Care Global Business Unit - Finviz
Teva And Sanofi Duvakitug Data Support IBD Pipeline And Growth Story - Sahm
RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell? - Finviz
SNY Stock Falls After Board Suddenly Makes Leadership Change - Finviz
Sanofi Pulls the Emergency Brake: What the Hudson Ouster and Garijo Appointment Really Mean for Investors - CTOL Digital Solutions
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? - Finviz
FDA Refuses To Review Moderna's Influenza Shot Application - Sahm
SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status - Finviz
Sanofi (SNY) Strengthens Shareholder Returns Amid Robust 2025 Performance and Long-Term Growth Outlook - Finviz
Is Sanofi SA (SNY) One of the Best Cheap Stocks to Buy for 2026 - Finviz
Sanofi Found In Breach Of UK Pharmaceutical Marketing Code Over Beyfortus Claims - Sahm
FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Sanofi Plans Regulatory Submission For Investigational Drug For Rare Disease Despite Mixed Data From Pivotal Trials - Sahm
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Resmed (RMD) and Sanofi (OtherSNYNF) - The Globe and Mail
REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth - Finviz
European ADRs Slip, But Still End The Week Higher - Finimize
Sanofi ADR earnings beat by $0.69, revenue fell short of estimates - Investing.com South Africa
SNY Stock Today: January 30 RSV Wave in Germany Puts Beyfortus in Focus - Meyka
TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth - Finviz
Earnings call transcript: Sanofi Q4 2025 earnings beat EPS forecast - Investing.com
Earnings Preview: Sanofi - Sahm
Berenberg Bank Remains a Buy on Sanofi (SNY) - Finviz
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer - Finviz
The Truth About Sanofi S.A.: Is This Pharma Giant the Sleeper Stock Everyone’s Sleeping On? - AD HOC NEWS
Sanofi (SNY) Secures Approval for Cablivi in the US and Plozasiran in China - Finviz
FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? - Finviz
Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week? - Finviz
Sanofi Adr Stock (SNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):